ProCE Banner Activity

GRIFFIN 2-Yr Maintenance Phase Update: Dara + VRd With Dara-R Maintenance vs VRd With R Maintenance for ASCT-Eligible Patients With Newly Diagnosed MM

Slideset Download
Conference Coverage
After 24 months of maintenance therapy, D-VRd continued to show deep and durable responses in transplant-eligible patients with ND MM.

Released: December 22, 2021

Expiration: December 21, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation